We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Offers Latest Innovations in Urinalysis and Automation at AACC 2021

By LabMedica International staff writers
Posted on 27 Sep 2021
Print article
Image: DxA 5000 Fit Workflow Automation System (Photo courtesy of Beckman Coulter)
Image: DxA 5000 Fit Workflow Automation System (Photo courtesy of Beckman Coulter)

Beckman Coulter, Inc. (Brea, CA, USA) displayed its latest innovations in urinalysis and automation that are designed to improve lab workflow at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

AACC 2021 was a live event held at the Georgia World Congress Center in Atlanta on September 26-30. At this year’s AACC Clinical Lab Expo, more than 700 exhibitors displayed the latest diagnostic technology, including but not limited to mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation. Beckman Coulter introduced its latest urinalysis solutions that continue to build upon its Iris legacy.

Beckman Coulter showcased its iRICELL series of automated walk-away workcells that delivers maximum efficiency and productivity for low- to high-volume labs. The iRICELL series combines urine chemistry and microscopy in a fully automated, walk-away workcell that is easy to use and maintain. It allows labs to optimize and advance urinalysis and body fluid testing with the company’s proprietary Digital Flow Morphology technology that uses Auto-particle Recognition (APR) software to deliver standardized and accurate results.

Beckman Coulter also highlighted its iQ200 series designed for low- to high-volume workloads, automating sample microscopy and producing shortened TAT. By leveraging its proprietary Digital Flow Morphology technology using Auto-Particle Recognition (APR) Software, urine particles are isolated, identified and characterized on the screen to virtually eliminate the need for manual microscopy. The iQ200 series analyzers are available as either stand-alone instruments or they can be connected to an iChemVELOCITY urine chemistry analyzer to form an automated iRICELL workcell.

Also on display at the event was Beckman Coulter’s iChemVELOCITY, a fully automated urine analyzer that provides results for ascorbic acid levels in samples. The iChemVELOCITY sets the standard for automated urine chemistry analysis with the development of the ascorbic acid test pad to identify possible ascorbic acid interference with key chemistry assays, ensuring laboratories receive clinically relevant information. This urine chemistry instrument offers high throughput of up to 210 samples per hour and ease of use to maximize lab performance and productivity.

Beckman Coulter also introduced the newest connection to DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day. The DxA 5000 Fit is designed for laboratories with space constraints, yet, its scalable design allows it to easily expand to accommodate growing workloads. With the DxA 5000 Fit, mid-sized labs can enjoy the same benefits as larger-volume labs.

Related Links:
Beckman Coulter, Inc.

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article
ADLM

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.